Alex Therapeutics
Alex Therapeutics is a company that provides a smarter way to launch Digital Therapeutics (DTx). They offer the Alex DTx Platform, which allows partners in the pharmaceutical and healthcare industries to effectively and reliably launch new DTx treatments by utilizing existing insights, modules, processes, and data. The company's DTx treatments are evidence-based therapeutic interventions delivered as mobile software applications and undergo rigorous clinical and regulatory review. Alex Therapeutics is currently conducting clinical trials in Germany for their Eila® program, a 12-week digital therapy for tobacco dependence. They also collaborate with others to provide a comprehensive DTx for treating symptoms associated with pulmonary fibrosis (PF). With a patient-centric approach, they aim to deliver targeted personalized care to patients with overlooked symptoms.
